A meta-analysis of randomized controlled trials demonstrated that treatment with n-3 polyunsaturated fatty acids (PUFAs) significantly increases circulating adiponectin in patients with type 2 diabetes [150]. Here, ADIPOQ is linked to type 2 diabetes mellitus.